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Abstract
Objective
To clarify the relationship among serum adiponectin, body composition, current disease
activity and therapeutics of rheumatoid arthritis (RA).
Methods
We conducted a cross-sectional study in RA patients under treatment with agents including
biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK)
inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort
(KURAMA) were enrolled in the analysis. We classified the participants into five body com-
position groups according to the cut-off points for obesity and visceral fat used in Japan:
body mass index (BMI), 18.5 kg/m2 for underweight and 25.0 kg/m2 for obesity, and visceral
fat area (VFA), 100 cm2 for visceral adiposity.
Results
Classification of body composition revealed that serum adiponectin levels and disease activ-
ity score (DAS28-ESR) in the low BMI group were significantly higher than those in the nor-
mal and overweight groups. Because both increased serum adiponectin and low BMI were
previously reported as poor prognostic factors of RA, we performed multiple regression
analysis to determine which factor was correlated with RA disease activity. Serum adiponec-
tin level, but not BMI, was positively associated with DAS28-ESR (estimate = 0.0127, p =
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0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an
obvious influence on circulating adiponectin.
Conclusions
Classification of body composition and multiple regression analysis revealed a positive and
independent correlation between serum adiponectin and DAS28-ESR in Japanese RA
patients. Thus, serum adiponectin may be an important marker reflecting high disease activ-
ity of RA regardless of current medications.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammatory
destruction of joints. Cytokine and T cell signaling pathways are pivotal mediators of RA [1],
and biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK)
inhibitors targeting the mediators have dramatically improved clinical outcomes [2, 3]. How-
ever, some patients continue to show insufficient response to several agents including the
newer ones, and the patients may have an unknown contributor to sustained high disease
activity.
Previous reports have revealed that low body mass index (BMI) is a poor prognostic factor
of RA. Several studies have demonstrated that low BMI associates with radiographic progres-
sion and mortality [4–6], and that greater BMI is associated with lower risk of joint damage [7,
8]. These unexpected and beneficial results are called the “obesity paradox”, as adipose tissue is
a potent source of pro-inflammatory cytokines such as tumor necrosis factor α (TNFα) and
interleukin-6 (IL-6) [9]. The underlying mechanisms of joint inflammation among under-
weight patients are unclear and require further investigation.
Recently, both clinical and basic studies have reported a relationship between RA and adi-
ponectin, a major adipokine secreted mainly from adipose tissue. Adiponectin possesses pleio-
tropic effects on inflammatory conditions of several chronic diseases. For example, it has anti-
atherogenic and anti-inflammatory effects on metabolic traits such as type 2 diabetes, meta-
bolic syndrome and cardiovascular disease [10–12]. However, conflicting effects on RA have
been reported, such as that increased adiponectin in the synovium induces pro-inflammatory
cytokines and matrix metalloproteinases (MMPs) [13, 14]. In clinical surveys on RA, some
authors have shown a statistical association between serum adiponectin levels and radio-
graphic joint destruction [15–17], but others have reported that hyperadiponectinemia does
not correlate with disease activity score (DAS28) [18–20]. Furthermore, the influence of thera-
peutic agents (i.e., bDMARDs and corticosteroids) on circulating adiponectin remains contra-
dictory [21–25].
As mentioned above, both low BMI and increased serum adiponectin have been reported
as poor prognostic factors of RA. It is also known that serum adiponectin levels inversely cor-
relate with BMI in general conditions and in patients with metabolic disorders including dia-
betes [26]. However, large-scale surveys of RA have not been done focusing on both BMI and
serum adiponectin, and it is unclear which factor provides further contribution to RA disease
activity. In addition, the effects of bDMARDs and JAK inhibitors on serum adiponectin levels
are largely unknown. We performed a cross-sectional study to clarify the relationship among
serum adiponectin, body composition, disease activity and therapeutic agents of RA patients.
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Material and methods
Ethical statement (study setting)
In the current study, we recruited outpatients with RA from the KURAMA (Kyoto University
Rheumatoid Arthritis Management Alliance) cohort. In brief, the KURAMA cohort was a pro-
spective study that was established in May 2011 at the Center for Rheumatic Diseases in Kyoto
University Hospital for the purpose of the proper control of RA and utilization of laboratory
and clinical data for clinical investigations [27]. This study was designed under the principals
of the Declaration Helsinki and approved by the Medical Ethics Committee of Kyoto Univer-
sity Graduate School and Faculty of Medicine (Approval number: R0357). All participants pro-
vided written informed consent.
Study population and design
All outpatients who were over 18 years old and fulfilled the 2010 American College of Rheu-
matology (ACR)/European League against Rheumatism (EULAR) classification criteria were
included between 1st May and 30th November 2016 (n = 441) [28]. After excluding 55 patients
without a complete data set, using an electronic device, fracture, pain, abdominal surgery or
pregnancy, which prevented measurement of body composition, and 35 with confounding
conditions or treatments such as dialysis treatment, hepatitis, sex-hormone suppression or
replacement therapy, psychiatric disorders and cognitive impairment, the remaining 351
patients were enrolled in this study.
Evaluation of serum adiponectin concentrations and RA-related factors
Total serum adiponectin level was measured using latex particle-enhanced turbidimetric immu-
noassay (LTIA) (SRL, Inc. Tokyo, Japan). We assessed disease activity and physical disability of
RA using the 28-Joint RA Disease Activity Score (DAS28-ESR) and the health assessment ques-
tionnaire-disability index (HAQ), respectively. Baseline values of serological data were evaluated
including rheumatoid factor (RF), matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated
peptide (anti-CCP antibody), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR),
estimated glomerular filtration (eGFR), hemoglobin (Hb) and albumin (Alb). We also reviewed
the use of therapeutic agents including methotrexate (MTX), prednisolone (PSL), TNF inhibitors
(infliximab, adalimumab, etanercept, certolizumab pegol, golimumab), IL-6 receptor inhibitor
(tocilizumab), cytotoxic T-lymphocyte antigen 4-immunoglobulin (abatacept), and JAK inhibitor
(tofacitinib). The only targeted synthetic DMARDs (tsDMARDs) used in the cohort were tofaciti-
nib, which was included in the biological agent category for statistical evaluation.
Data collection and classification of body composition
We measured height, weight, waist circumference (WC), and indicators of body composition
including visceral fat area (VFA), subcutaneous fat area (SFA) and skeletal muscle ratio (SMR)
with standardized protocols, as previously described [29].
Briefly, WC was measured at the navel position with a non-stretchable tape while standing.
VFA and SFA were measured with a dual bioelectrical impedance analyzer (HDS-2000 DUALS-
CAN, Omron Healthcare Co., Japan), and the skeletal muscle mass was assessed by a Z impedance
analyzer (HBF-701 KARADASCAN, Omron Healthcare Co., Japan) [30]. SMR was calculated by
dividing the skeletal muscle mass by body weight. With these indicators, we classified RA outpa-
tients into five body composition groups according to the criteria for obesity and visceral fat in
Japan [31]. Specifically, we divided RA outpatients using cut-off points of BMI (18.5 kg/m2 for
underweight and 25.0 kg/m2 for obesity) and VFA (100 cm2 for visceral adiposity).
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Statistical analysis
Data were described as the mean ± standard deviation (SD) for continuous variables and num-
bers (%) for categorical variables. Differences in body composition groups and comparisons of
adiponectin levels among types of treatments were assessed by a Steel-Dwass test or one-way
analysis of variance (ANOVA) for continuous variables, or Fisher’s exact test for categorical
variables. To analyze effects of serum adiponectin levels on RA disease activity (DAS28-ESR),
we adopted a multiple standardized linear regression model with identity link and exponential
distribution including demographic factors (age, sex, body mass index, VFA/SFA ratio), RA-
related-factors (RA duration, RF, anti-CCP antibody and presence or absence of biological
agents, MTX and PSL), life style-related factors (diabetes mellitus, hypertension, dyslipidemia
and smoking habit) and serological factors (adiponectin, eGFR). In subgroup analysis accord-
ing to sex, we selected variables for multiple regression analysis including RF, anti-CCP anti-
body, age, body mass index and adiponectin. We included possible covariates previously
reported in the analysis, and eliminated multicollinearity as detected by variance inflation fac-
tor>10. All statistical analyses were performed by JMP1 14 (SAS Institute Inc., Cary, NC,
USA) and P values< 0.05 were considered significant.
Results
Baseline characteristics of RA outpatients in this study
The included data of 351 patients (291 women, 60 men) were subjected to the following analy-
sis. The baseline characteristics are described in Table 1. The average age was 61.8 years and
the average RA disease duration was 10.6 years. BMI and DAS28-ESR of the enrolled patients
were generally low compared to those in previous reports. [16, 32] In current therapeutics,
usage rates of MTX, bDMARDs, and PSL are 72.6, 52.4, and 20.8% respectively, and there are
newer biological agents including anti-TNFα treatments and anti-IL-6 treatments.
Serum adiponectin levels and RA disease activity are highest in the low
BMI group
Next, to understand whether body composition of RA patients affects RA disease activity and
serum adiponectin levels, we divided the 351 patients into five body composition phenotypes:
underweight (BMI < 18.5, VFA < 100), normal weight (+) visceral adiposity (-) (18.5�
BMI< 25, VFA < 100), normal weight (+) visceral adiposity (+) (18.5� BMI< 25, VFA�
100), overweight (+) visceral adiposity (-) (25 < BMI, VFA < 100), and overweight (+) visceral
adiposity (+) (25< BMI, VFA� 100) (Table 2). No significant differences were detected in
age, RA-duration, or current RA medications among the various body composition groups. In
contrast, both serum adiponectin levels and DAS28-ESR were significantly higher only in the
underweight group compared to the others (mean ± SD, 20.9 ± 12.5, p = 0.017 for adiponectin,
and mean ± SD, 3.04 ± 1.03, p< 0.001 for DAS28-ESR). Hence, RA patients with low body
weight had remarkably higher serum adiponectin levels along with higher RA disease activity
than those with normal weight or obesity.
Serum adiponectin levels rather than BMI may be independently associated
with DAS28-ESR
Previous studies had reported that serum adiponectin levels were negatively correlated to BMI
in general conditions, and that both increased serum adiponectin and low BMI were poor
prognostic factors of RA progression. To determine whether serum adiponectin levels were
independently related with RA disease activity, we performed multiple regression analysis.
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Table 1. Basic demographical and clinical characteristics of study population.
RA patients
Items (N = 351)
Age, years 61.8 ± 12.0
Male, n (%) 60.0 (17.1)
Body composition parameters
BMI, kg/m2 22.6 ± 3.7
VFA, cm2 62.0 ± 32.5
SFA, cm2 153.6 ± 69.9
V/S ratio 0.43 ± 0.19
Systemic skeletal muscle ratio, % 24.6 ± 3.2
Body fat percentage, %
Male 24.8 ± 5.6
Female 32.1 ± 5.0
Waist circumference, cm 84.2 ± 10.2
Laboratory data
Hemoglobin, g/dL 12.8 ± 1.5
Albumin, g/dL 4.03 ± 0.30
eGFR, ml/min/1.73m2 74.5 ± 18.1
Adiponectin, μg/mL 14.8 ± 8.5
Comorbidities
Hypertension, n (%) 113 (32.2)
Diabetes Mellitus, n (%) 29 (8.3)
Dyslipidemia, n (%) 130 (37.0)
Smoking habit, n (%) 29 (8.2)
RA disease characteristics
Duration, years 10.6 ± 9.5
RF, IU/mL 39.2 (8–2833.6)
MMP-3, ng/mL 56.8 (18.2–633.6)
Anti-CCP antibody, U/mL 51 (0.6–3260)
CRP, mg/dL 0.1 (0.1–9.6)
DAS28-ESR 2.52 (0.33–7.20)
HAQ score 0.29 (0–2.50)
Stage� 2.40 ± 1.16
Class� 1.52 ± 0.59
Current RA therapeutics
MTX use, n (%) 255 (72.6)
Dose of MTX use, mg/day (mean of users) 8 (2–16)
Other cs DMARDs use, n (%) 46 (13.1)
ts DMARDs use, n (%) 2 (1.0)
Prednisoline use, n (%) 73 (20.8)
Dose of Prednisolone use, mg/day (mean of users) 4 (1–10)
Biological agent use, n (%) 184 (52.4)
Abatacept, n 38
Adalimumab, n 14
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With DAS28-ESR as the dependent variable, serum adiponectin level, but not BMI, was signif-
icantly associated with higher DAS28-ESR (Table 3). In addition, age, PSL use, RF, anti-CCP
antibody and eGFR were positively associated, and male sex was negatively associated with
DAS28-ESR as independent variables. In subgroup analysis based on sex differences, we also
found that serum adiponectin level was independently correlated with DAS28-ESR in female
patients as well as in male ones (S1 Table). These results suggest that the serum adiponectin
level may be an important parameter in terms of assessment of RA disease state.
Circulating adiponectin levels are not affected by biological agents
In addition, we assessed the influence of bDMARDs and JAK inhibitor on serum adiponectin
levels. Fig 1 shows the histogram of serum adiponectin levels of patients divided into each
treatment group. Although previous studies have shown that serum adiponectin levels are
affected by RA therapeutics such as anti-TNFα treatments [22, 25], our data indicate that bio-
logical agents and JAK inhibitor do not significantly affect serum adiponectin levels.
Discussion
In order to evaluate the relationship among serum adiponectin, body composition and RA dis-
ease activity, we performed a cross-sectional survey of a Japanese RA population under treat-
ment. Classification of body composition revealed that DAS28-ESR and serum adiponectin
levels were significantly increased only in the underweight group (BMI < 18.5, VFA < 100).
Accounting for covariates including BMI, serology and therapeutics, multiple regression anal-
ysis showed a positive correlation between DAS28-ESR and serum adiponectin. These results
correspond to previous findings that patients with lower BMI have exacerbated disease pro-
gression [5, 6], and demonstrate that serum adiponectin, rather than BMI, may be a main con-
tributor to the disease activity regardless of current medication.
In addition to serum adiponectin, other independent variables were also associated with
DAS28-ESR in multiple regression analysis, such as PSL use, RF, anti-CCP antibody, age, sex
and eGFR (Table 3). The long-term use of PSL potentially has multiple adverse effects, and its
use is usually limited to refractory patients with high disease activity according to clinical rec-
ommendations [3]. Previous studies have also reported that high titers of RF or anti-CCP anti-
body are poor prognostic factors [33], and that greater age and female sex are independently
associated with the increased ESR levels in RA patients [34]. Furthermore, eGFR levels are
Table 1. (Continued)
RA patients




Continuous variable data are presented as mean (± SD), and categorical variables are shown as numbers (%). Data of
RA characteristics and current therapeutics are expressed as median (range).
RA rheumatoid arthritis, BMI body mass index, VFA visceral fat area, SFA subcutaneous fat area, V/S ratio visceral/
subcutaneous fat area, eGFR estimated glomerular filtration, RF rheumatoid factor, MMP-3 matrix metalloproteinase
3, anti-CCP antibody anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, DAS28-ESR 28-joint disease
activity score using erythrocyte sedimentation rate, HAQ health assessment questionnaire, MTX methotrexate,
csDMARD conventional synthetic disease modifying anti-rheumatic drugs, tsDMARD targeted synthetic DMARD
�Steinbrocker’s stage and class
https://doi.org/10.1371/journal.pone.0229998.t001
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generally overestimated in lean populations, and thus its levels may be highest in the under-
weight group with high disease activity (Table 2).
There was no significant difference of serum adiponectin level between normal weight and
overweight in the body composition analysis, although its level inversely correlated with BMI
and VFA in the whole population of our study (data not shown) as well as in previous studies
[35, 36]. These findings may be attributed to several reasons. First, the relationship between
serum adiponectin level and BMI/VFA shows exponential decay as previously reported [11],
and thus the difference of its level gets smaller according to weight gain. Second, the number
Table 2. Baseline demographics of RA patients stratified by body composition phenotype (VFA and BMI).
Underweight Normal weight Overweight
BMI < 18.5 18.5� BMI < 25 BMI� 25 p value �
VFA < 100 VFA < 100 VFA� 100 VFA < 100 VFA� 100
Visceral adiposity (-) (-) (+) (-) (+)
(N = 351) n = 37 (10.5%) n = 223 (63.5%) n = 12 (3.4%) n = 43 (12.3%) n = 36 (10.3%)
Age, year 61.3 ± 13.3 61.2 ± 12.2 71.8 ± 6.7 61.7 ± 11.6 62.9 ± 9.8 0.0501
Sex, n (Male/Female) 1/36 31/192 7/5 5/38 16/20 < 0.001
Body composition parameters
VFA, cm2 33.7 ± 15.0 50.7 ± 19.1 113.8 ± 13.6 77.1 ± 15.2 125.5 ± 26.4 < 0.001
SFA, cm2 69.6 ± 25.7 138.0 ± 47.9 156.9 ± 39.8 230.7 ± 57.3 244.0± 67.1 < 0.001
V/S ratio 0.68 ± 0.47 0.40 ± 0.17 0.76 ± 0.16 0.35 ± 0.12 0.55 ± 0.16 < 0.001
Systemic skeletal muscle ratio, % 25.5 ± 3.3 24.8 ± 3.2 25.8 ± 3.3 23.1 ± 3.4 24.6 ± 3.5 0.006
Waist circumference, cm
Male 63.0 ± 0.0 83.4 ± 6.0 87.9 ± 3.9 90.9 ± 6.7 98.1 ± 5.5 < 0.001
Female 71.0 ± 5.1 81.5 ± 7.3 92.4 ± 4.5 94.0 ± 7.2 100.0 ± 6.9 < 0.001
Laboratory data
Hemoglobin, g/dL 12.2 ± 1.5 12.6 ± 1.4 13.2 ± 1.2 13.4 ± 1.6 13.8 ± 1.6 < 0.001
Albumin, g/dL 3.98 ± 0.35 4.02 ± 0.31 4.05 ± 0.20 4.04 ± 0.26 4.08 ± 0.31 0.762
eGFR, ml/min/1.73m2 79.2 ± 22.4 74.7 ± 17.8 70.3 ± 13.3 73.1 ± 17.1 72.0 ± 17.1 0.386
Adiponectin, μg/mL 20.9 ± 12.5�� 14.8 ± 7.9 12.3 ± 6.1 11.8 ± 5.9 12.8 ± 7.5 < 0.001
RA disease characteristics
Disease duration, year 11.1 ± 7.8 10.5 ± 10.0 11.0 ± 8.7 12.0 ± 10.3 9.0 ± 7.1 0.716
HAQ score 0.66 ± 0.62 0.45 ± 0.55 0.69 ± 0.69 0.48 ± 0.60 0.51 ± 0.59 0.229
CRP, mg/dl 0.66 ± 1.81 0.33 ± 0.75 0.33 ± 0.38 0.26 ± 0.33 0.39 ± 0.54 0.243
DAS28-ESR 3.04 ± 1.03§ 2.60 ± 0.90 2.84 ± 0.87 2.72 ± 0.98 2.32 ± 0.98 0.017
Current therapeutic agent
csDMARD use, n (%) 32 (86.5) 196 (87.9) 9 (75.0) 35 (81.4) 29 (80.1) 0.4886
tsDMARD use, n (%) 0 (0) 2 (0.9) 0 (0) 0 (0) 0 (0) 0.887
Biological agent use, n (%) 21 (56.8) 114 (51.1) 6 (50.0) 22 (51.2) 19 (52.8) 0.979
Prednisolone use, n (%) 9 (24.3) 36 (16.1) 4 (33.3) 13 (30.2) 11 (30.6) 0.067
Data are expressed as mean ± SD, or number (%) BMI body mass index, VFA visceral fat area, SFA subcutaneous fat, V/S visceral/subcutaneous fat area, eGFR estimated
glomerular filtration, HAQ health assessment questionnaire, CRP C-reactive protein, DAS28-ESR disease activity score in 28 joints using erythrocyte sedimentation rate,
csDMARD conventional synthetic disease modifying anti-rheumatic drugs, tsDMARD targeted synthetic DMARD
�p-values for analysis of variance (ANOVA) for continuous variables or Fisher’s exact test for categorical variables
��p < 0.05 for multiple comparisons using Steel–Dwass test with the group of normal weight/visceral adiposity (-), overweight/visceral adiposity (-) and overweight/
visceral adiposity (+), p = 0.028, p = 0.003, p = 0.028, respectively
§p < 0.05 for multiple comparisons using Steel–Dwass test with normal weight/visceral adiposity (-) and overweight/visceral adiposity (+), p = 0.041, p = 0.019,
respectively
https://doi.org/10.1371/journal.pone.0229998.t002
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of subjects in each body composition is unbalance and might not be enough to show the statis-
tically significant difference.
Subanalysis of therapeutic agents indicates that they do not have an obvious influence on
circulating adiponectin. Other biomarkers such as MMP-3, TNFα, IL-6 and CRP are more or
Table 3. Multiple regression analysis for independent factors associated with DAS28-ESR.
Dependent variables Independent variables 95%CI
Estimates Std. Error p-value Lower Upper
DAS28-ESR Prednisolone (+) 0.553 0.117 < .0001 0.323 0.782
RF (1 IU/mL) 0.0007 0.00001 < .0001 0.00028 0.00099
Age (10 years) 0.171 0.049 < .0001 0.075 0.27
eGFR (10 ml/min/1.73m2) 0.083 0.028 0.0033 0.028 0.14
Sex (male) -0.406 0.14 0.0037 -0.68 -0.13
Adiponectin (1 μg/mL) 0.0127 0.0057 0.0258 0.0015 0.024
Anti-CCP antibody (10 U/mL) 0.0025 0.0011 0.0259 0.0003 0.0047
Covariates were selected from demographic, RA activity-related and life style-related factors: age, sex, body mass index, V/S ratio, eGFR, RA duration, RF, anti-CCP
antibody, biological agent use, MTX use, PSL use, diabetes mellitus, hypertension, dyslipidemia, smoking habit and adiponectin. Units for estimates values are expressed
in units in parentheses.
RF rheumatoid factor, eGFR estimated glomerular filtration rate, anti-CCP antibody anti-cyclic citrullinated peptide antibody.
https://doi.org/10.1371/journal.pone.0229998.t003
Fig 1. Box-and-whisker plots of serum adiponectin levels for subjects by use of biological agents (A) and type of biological agent (B).
Boxplots show IQR from the 1st quartile to the 3rd quartile. Whiskers are drawn to the 5th percentile and 95th percentile point. Mean serum
adiponectin levels did not differ significantly between users of biological agents and non-users (A), or among kinds of biological agent (B). Bio
biological agents, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ
tocilizumab, TOF tofacitinib, TNF tumor necrosis factor, N.S. not significant.
https://doi.org/10.1371/journal.pone.0229998.g001
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less interfered with by PSL, TNF inhibitors and IL-6 inhibitors, and may not necessarily reflect
disease activity states of RA. Even though further longitudinal studies are needed, serum adi-
ponectin seems to be a novel activity marker regardless of therapeutic agents.
Although it has been generally accepted that adiponectin has an anti-atherogenic and anti-
inflammatory effect, recent clinical and basic research has indicated a deleterious role of adipo-
nectin under inflammatory conditions. Epidemiological studies have reported a positive asso-
ciation between circulating adiponectin and all-cause mortality on several chronic diseases
such as cardiovascular disease, type 2 diabetes and chronic kidney disease [37]. Another survey
on RA has revealed that serum adiponectin significantly correlates with radiographic damage,
but that other adipokines (resistin and leptin) do not [16]. Furthermore, in vitro studies have
shown that adiponectin induces MMP-3, IL-6 and monocyte chemotactic protein-1 (MCP-1)
expression in human chondrocytes [13, 38]. Klaus et al. have also proved that adiponectin pro-
motes higher-yield secretion of chemical mediators (i.e., MCP-1, IL-6, IL-8 and MMP-3) from
RA synovial fibroblasts compared to those in osteoarthritis, and that it induces lymphocytes to
synthesize TNFα, IL-6 and IL-8 [39]. These results suggest that adiponectin plays a potential
pathophysiological role in RA.
In the present study, the classification of body composition revealed the relationship
among BMI, serum adiponectin and RA disease activity. Using the same classification method,
Fig 2. A proposed cycle model of the exacerbation of rheumatoid arthritis in terms of adiponectin.
Hyperadiponectinemia enhances inflammation and cytokine/chemokine production in RA synovial joints. These
inflammatory mediators induce loss of body weight including white adipose tissue, and additional adiponectin is
secreted from the remaining white adipose tissue. This cycle of exacerbation may occur especially in RA patients
having low body weight. TNF tumor necrosis factor, IL-6 interleuin-6, MCP-1 Monocyte Chemotactic Protein-1.
https://doi.org/10.1371/journal.pone.0229998.g002
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our group previously showed that RA patients with low BMI had minimal scores of carotid
atherosclerosis [29]. These results indicate that underweight RA have the highest disease activ-
ity and minimal atherogenic change. It seems to implicate a biphasic mediator in its pathogen-
esis; that is, hyperadiponectinemia may protect against systemic atherosclerosis but drive
cytokine production from affected joints, resulting in body weight loss followed by additional
secretion of circulating adiponectin (Fig 2).
There are several notable limitations in our study. This is a cross-sectional clinical study
without longitudinal data, and our results do not imply causation. The long-term influence of
each bDMARD or JAK inhibitor on serum adiponectin is still unknown, and the pathophysiologi-
cal role of adiponectin in RA progression needs further investigation including in vitro studies. In
our university hospital, the frequency of bDMARDs use exceeds 50% and might differ from that
in other medical institutions. It is unclear whether our findings can be generalized to any other
population, because Japanese have the lowest average BMI among developed countries, and
because more than half of our participants is in one of the five groups (normal weight and
VFA<100). Finally, there might be unconsidered covariates affecting RA severity or serum adipo-
nectin such as genetic variants (i.e., RA risk HLA alleles, and SNPs in adiponectin genes) [40, 41].
In conclusion, classification of body composition and multiple regression analysis showed a
positive and independent correlation between serum adiponectin and DAS28-ESR, and bio-
logical agents did not affect serum adiponectin levels. Therefore, measurement of serum adi-
ponectin may be potentially useful for assessing disease activity of RA regardless of current
medications.
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